Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
UNIVERSITA' DEGLI STUDI DI TORINO maintains a portfolio focused on Biotechnology & Pharmaceuticals. The university currently faces 2 pending office actions distributed across 2 distinct examiners. Despite the involvement of multiple examiners, all activity is centralized within 1 distinct art unit. This concentration suggests a specific technological focus within the broader biotechnology sector.
ARNOLD, ERNST V is identified as the busiest examiner for the portfolio, currently handling 1 busiest examiner pending action. This represents half of the total 2 pending office actions. The presence of 2 distinct examiners across 1 distinct art unit indicates that while the technology is specialized, the patent office has assigned multiple individuals to review the university's applications. For a practitioner, this means managing consistent arguments across different examiners within the same technical group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695235 | DNA VACCINE FOR USE IN THE THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF TUMOR DISEASES | KELLY, ROBERT M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721678 | METHOD FOR THE PREPARATION OF HYBRID POLYMERIC NANOPARTICLES FOR THE RELEASE OF OLIGONUCLEOTIDE DRUGS IN PHARMACOLOGICAL THERAPIES FOR REGENERATIVE, CURATIVE, AND PREVENTIVE PURPOSES | ARNOLD, ERNST V | — |
| 18695235 | DNA VACCINE FOR USE IN THE THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF TUMOR DISEASES | KELLY, ROBERT M | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18721678 | METHOD FOR THE PREPARATION OF HYBRID POLYMERIC NANOPARTICLES FOR THE RELEASE OF OLIGONUCLEOTIDE DRUGS IN PHARMACOLOGICAL THERAPIES FOR REGENERATIVE, CURATIVE, AND PREVENTIVE PURPOSES | ARNOLD, ERNST V | 1613 | §103 | Non-Final OA | — | Pending | Jun 19, 2024 |
| 18695235 | DNA VACCINE FOR USE IN THE THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF TUMOR DISEASES | KELLY, ROBERT M | — | §102§103§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial